RxDoctor Payments Data

Jodi Carson

Psychiatric/Mental Health · Clifton Park, NYNPI 1609521145

Payments from drug & device makers

$4,863in general payments, 2019–2025

Across 216 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$786
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$474
  • Otsuka America Pharmaceutical, Inc.$450
  • Neurocrine Biosciences, Inc.$296
  • Alkermes, Inc.$290
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,863 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$44,681
Medicare patients
39
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide19$17,195
VyvanseLisdexamfetamine Dimesylate17$6,419
Duloxetine Hcl50$2,398
Bupropion XlBupropion Hcl104$2,079
Aripiprazole32$1,523
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine47$1,357
Quetiapine Fumarate94$1,312
Methylphenidate ErMethylphenidate Hcl13$1,109
Mirtazapine72$995
Bupropion Hcl SrBupropion Hcl32$843
Fluoxetine Hcl51$842
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine45$822
Olanzapine35$753
Trazodone Hcl82$640
Escitalopram Oxalate59$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$252$23,61436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Clifton Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →